AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.
Research Site, Fitzroy, Victoria, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.